Antibody Responses After a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia

Overview

Journal Vaccines (Basel)

Date 2021 Oct 26

PMID 34696163

Citations 30

Authors

Julien Marlet

Philippe Gatault

Zoha Maakaroun

Helene Longuet

Karl Stefic

Lynda Handala

Sebastien Eymieux

Emmanuel Gyan

Caroline Dartigeas

Catherine Gaudy-Graffin

Affiliations

Soon will be listed here.

Abstract

The impact of a third dose of COVID-19 vaccine on antibody responses is unclear in immunocompromised patients. The objective of this retrospective study was to characterize antibody responses induced by a third dose of mRNA COVID-19 vaccine in 160 kidney transplant recipients and 20 patients treated for chronic lymphocytic leukemia (CLL). Prevalence of anti-spike IgG ≥ 7.1 and ≥ 30 BAU/mL after the third dose were 47% (75/160) and 39% (63/160) in kidney transplant recipients, and 57% (29/51) and 50% (10/20) in patients treated for CLL. Longitudinal follow-up identified a moderate increase in SARS-CoV-2 anti-spike IgG levels after a third dose of vaccine in kidney transplant recipients (0.19 vs. 5.28 BAU/mL, = 0.03) and in patients treated for CLL (0.63 vs. 10.7 BAU/mL, = 0.0002). This increase in IgG levels had a limited impact on prevalence of anti-spike IgG ≥ 30 BAU/mL in kidney transplant recipients (17%, 2/12 vs. 33%, 4/12, = 0.64) and in patients treated for CLL (5%, 1/20 vs. 45%, 9/20, = 0.008). These results highlight the need for vaccination of the general population and the importance of non-medical preventive measures to protect immunocompromised patients.

Citing Articles

Immunogenicity and Safety of the Three-Dose COVID-19 Vaccine Regimen in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis.

Ma B, Tam A, Chan K, Hung I, Tang S, Chan T Kidney Dis (Basel). 2024; 10(2):107-117.

PMID: 38751793 PMC: 11095616. DOI: 10.1159/000536308.

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).

Kijak G, Ahani B, Arbetter D, Chuecos F, Gopalakrishnan V, Beloor J Infect Dis Ther. 2023; 12(12):2691-2707.

PMID: 37914983 PMC: 10746613. DOI: 10.1007/s40121-023-00882-2.

Delayed and Attenuated Antibody Responses to Coronavirus Disease 2019 Vaccination With Poor Cross-Variant Neutralization in Solid-Organ Transplant Recipients-A Prospective Longitudinal Study.

Liew M, Mathews J, Li A, Singh R, Jaramillo S, Weiss Z Open Forum Infect Dis. 2023; 10(8):ofad369.

PMID: 37577118 PMC: 10414143. DOI: 10.1093/ofid/ofad369.

Factors associated with the humoral response after three doses of COVID-19 vaccination in kidney transplant recipients.

Bulnes-Ramos A, Pozo-Balado M, Olivas-Martinez I, Garrido-Rodriguez V, Bernal-Blanco G, Suarez-Benjumea A Front Immunol. 2023; 14:1099079.

PMID: 36875099 PMC: 9977967. DOI: 10.3389/fimmu.2023.1099079.

Prevalence of COVID-19 in Kidney Transplant Patients in Relation to Their Immune Status after Repeated Anti-SARS-CoV-2 Vaccination.

Sakalauskaite S, Vaiciuniene R, Kusleikaite-Pere N, Narbutiene J, Sauseriene J, Aukstakalniene A Pathogens. 2023; 12(2).

PMID: 36839623 PMC: 9966983. DOI: 10.3390/pathogens12020351.

References

Gobbi F, Buonfrate D, Moro L, Rodari P, Piubelli C, Caldrer S . Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection. Viruses. 2021; 13(3). PMC: 8001674. DOI: 10.3390/v13030422. View

Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A . Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med. 2021; 385(7):661-662. PMC: 8262620. DOI: 10.1056/NEJMc2108861. View

Benotmane I, Gautier G, Perrin P, Olagne J, Cognard N, Fafi-Kremer S . Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. JAMA. 2021; . PMC: 8456389. DOI: 10.1001/jama.2021.12339. View

Agha M, Blake M, Chilleo C, Wells A, Haidar G . Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era. Open Forum Infect Dis. 2021; 8(7):ofab353. PMC: 8320282. DOI: 10.1093/ofid/ofab353. View

Roeker L, Knorr D, Thompson M, Nivar M, Lebowitz S, Peters N . COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia. 2021; 35(9):2703-2705. PMC: 8118367. DOI: 10.1038/s41375-021-01270-w. View

Grupper A, Rabinowich L, Schwartz D, Schwartz I, Ben-Yehoyada M, Shashar M . Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021; 21(8):2719-2726. PMC: 8250589. DOI: 10.1111/ajt.16615. View

Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M . Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. J Am Soc Nephrol. 2021; 32(9):2153-2158. PMC: 8729854. DOI: 10.1681/ASN.2021040490. View

Haas E, Angulo F, McLaughlin J, Anis E, Singer S, Khan F . Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021; 397(10287):1819-1829. PMC: 8099315. DOI: 10.1016/S0140-6736(21)00947-8. View

Feng S, Phillips D, White T, Sayal H, Aley P, Bibi S . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(11):2032-2040. PMC: 8604724. DOI: 10.1038/s41591-021-01540-1. View

10.

Tenforde M, Olson S, Self W, Talbot H, Lindsell C, Steingrub J . Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(18):674-679. PMC: 9368749. DOI: 10.15585/mmwr.mm7018e1. View

11.

Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R . Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays. Microbiol Spectr. 2021; 9(1):e0024721. PMC: 8552734. DOI: 10.1128/Spectrum.00247-21. View

12.

Stumpf J, Siepmann T, Lindner T, Karger C, Schwobel J, Anders L . Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur. 2021; 9:100178. PMC: 8299287. DOI: 10.1016/j.lanepe.2021.100178. View

13.

Kristiansen P, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K . WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021; 397(10282):1347-1348. PMC: 7987302. DOI: 10.1016/S0140-6736(21)00527-4. View

14.

Qin C, Moore L, Anjan S, Rahamimov R, Sifri C, Ali N . Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. Transplantation. 2021; 105(11):e265-e266. PMC: 8549120. DOI: 10.1097/TP.0000000000003907. View

15.

Narasimhan M, Mahimainathan L, Araj E, Clark A, Markantonis J, Green A . Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups. J Clin Microbiol. 2021; 59(7):e0038821. PMC: 8218760. DOI: 10.1128/JCM.00388-21. View

16.

Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E . Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021; 373:n1088. PMC: 8116636. DOI: 10.1136/bmj.n1088. View

17.

Prendecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M . Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021; 397(10280):1178-1181. PMC: 7993933. DOI: 10.1016/S0140-6736(21)00502-X. View

18.

Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y . Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021; 137(23):3165-3173. PMC: 8061088. DOI: 10.1182/blood.2021011568. View

19.

Werbel W, Boyarsky B, Ou M, Massie A, Tobian A, Garonzik-Wang J . Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann Intern Med. 2021; 174(9):1330-1332. PMC: 8252023. DOI: 10.7326/L21-0282. View